Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Oligodendroglioma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 66Radiotherapy 34Carboplatin 22Carmustine 21Bevacizumab 21Irinotecan 18Filgrastim 18Surgical Procedures, Operative 14Vincristine 11Peripheral Blood Stem Cell Transplantation 11Etoposide 11Radiation 10O(6)-benzylguanine 10Magnetic Resonance Spectroscopy 9Lomustine 9Procarbazine 8Erlotinib Hydrochloride 8sargramostim 7IL13-PE38 7Everolimus 7Cyclophosphamide 7Chemotherapy, Adjuvant 7Thiotepa 6Radiotherapy, Intensity-Modulated 6Imatinib Mesylate 6Granulocyte Colony-Stimulating Factor 6Drug Therapy 6Cisplatin 6temsirolimus 5antineoplaston AS 2-1 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Astrocytoma × efaproxiral × Clear all
NCT00005855 2013-06-21

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡